August 29, 2015
LONDON — In a new guideline, the European Society of Cardiology and the European Respiratory Society outline a treatment algorithm for pulmonary hypertension and offer advice on when to use newly approved drugs.
Since the release of previous guidelines in 2009, “a huge amount of evidence has accumulated on the pharmacological treatment of patients with PAH [pulmonary arterial hypertension]. We have reconciled all the available data in a comprehensive treatment algorithm and in multiple tables that give recommendations for different patient risk profiles,” Nazzareno Galiè, MD, associate professor of cardiology at the University of Bologna, Italy, and chairperson of the task force that wrote the document, said in a press release. “The information is inclusive enough to be applicable in different health care systems with heterogeneous drug availability. The algorithm for [chronic thromboembolic pulmonary hypertension] is more detailed and recommends specific imaging tests to better define the treatment strategy."